{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:14:01Z","timestamp":1782818041768,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2025ZD1800503"],"award-info":[{"award-number":["2025ZD1800503"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jconrel.2026.114873","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:46:15Z","timestamp":1774583175000},"page":"114873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["\u03b2-glucuronidase-triggered ortho-hydroxyl-mediated cyclization strategy for the efficient delivery of phenolic payloads in antibody-drug conjugates"],"prefix":"10.1016","volume":"394","author":[{"given":"Taiwen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jconrel.2026.114873_bb0005","first-page":"327","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy. Nature reviews","volume":"18","author":"Drago","year":"2021","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114873_bb0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114873_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114873_bb0020","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nbt.3040","article-title":"Biopharmaceutical benchmarks 2014","volume":"32","author":"Walsh","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114873_bb0025","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/CCO.0000000000001065","article-title":"Update of antibody-drug conjugates for hematological malignancies","volume":"36","author":"Sun","year":"2024","journal-title":"Curr. Opin. Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114873_bb0030","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: a dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114873_bb0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114873_bb0040","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2026.114873_bb0045","series-title":"Methods in Molecular Biology (Clifton, N.J.)","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-62703-541-5_5","article-title":"Linker technologies for antibody-drug conjugates","volume":"1045","author":"Nolting","year":"2013"},{"issue":"16","key":"10.1016\/j.jconrel.2026.114873_bb0050","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114873_bb0055","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.jconrel.2026.114873_bb0060","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114873_bb0065","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.bmcl.2016.02.020","article-title":"Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads","volume":"26","author":"Nakada","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114873_bb0070","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-Labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114873_bb0075","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114873_bb0080","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114873_bb0085","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114873_bb0090","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an Anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"21","key":"10.1016\/j.jconrel.2026.114873_bb0095","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/jm800719t","article-title":"Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy","volume":"51","author":"Moon","year":"2008","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.jconrel.2026.114873_bb0100","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114873_bb0105","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/mp500781a","article-title":"Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985","volume":"12","author":"Elgersma","year":"2015","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114873_bb0110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1535-7163.MCT-14-0881-T","article-title":"The preclinical profile of the duocarmycin-based HER2-Targeting ADC SYD985 predicts for clinical benefit in low HER2-Expressing breast cancers","volume":"14","author":"van der Lee","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114873_bb0115","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114873_bb0120","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bmcl.2005.09.081","article-title":"Dipeptide-based highly potent doxorubicin antibody conjugates","volume":"16","author":"Jeffrey","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2026.114873_bb0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejmech.2013.12.045","article-title":"\u03b2-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update","volume":"74","author":"Tranoy-Opalinski","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114873_bb0130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114873_bb0135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/bc400439x","article-title":"Auristatin antibody drug conjugate physical instability and the role of drug payload","volume":"25","author":"Adem","year":"2014","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114873_bb0140","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.jconrel.2026.114873_bb0145","first-page":"3541","article-title":"Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues","volume":"53","author":"Albin","year":"1993","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114873_bb0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s002100000260","article-title":"Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting","volume":"362","author":"Sperker","year":"2000","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114873_bb0155","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1158\/1535-7163.MCT-14-0212","article-title":"PET imaging of \u03b2-glucuronidase activity by an activity-based 124I-trapping probe for the personalized glucuronide prodrug targeted therapy","volume":"13","author":"Su","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114873_bb0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114873_bb0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/acs.bioconjchem.4c00392","article-title":"PEGylation of dipeptide linker improves therapeutic index and pharmacokinetics of antibody-drug conjugates","volume":"36","author":"Long","year":"2025","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114873_bb0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.jconrel.2026.114873_bb0175","doi-asserted-by":"crossref","first-page":"11018","DOI":"10.1158\/0008-5472.CAN-05-0491","article-title":"Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase\/AKT signaling pathway in breast cancer cells","volume":"65","author":"Asanuma","year":"2005","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.jconrel.2026.114873_bb0180","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1158\/1078-0432.CCR-05-2404","article-title":"Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells","volume":"12","author":"Erjala","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114873_bb0185","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1158\/0008-5472.CAN-08-3199","article-title":"Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma","volume":"69","author":"Sheu","year":"2009","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114873_bb0190","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114873_bb0195","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jacsau.2c00448","article-title":"40 years of duocarmycins: a graphical structure\/function review of their chemical evolution, from SAR to prodrugs and ADCs","volume":"2","author":"Felber","year":"2022","journal-title":"JACS Au"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114873_bb0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01954881","article-title":"Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4","volume":"45","author":"Pettit","year":"1989","journal-title":"Experientia"},{"key":"10.1016\/j.jconrel.2026.114873_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113355","article-title":"Combretastatin A4-derived payloads for antibody-drug conjugates","volume":"216","author":"Huang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114873_bb0210","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jconrel.2024.04.019","article-title":"Enhancing SN38 prodrug delivery using a self-immolative linker and endogenous albumin transport","volume":"369","author":"Jiang","year":"2024","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2026.114873_bb0215","doi-asserted-by":"crossref","first-page":"8361","DOI":"10.1021\/acs.jmedchem.4c03096","article-title":"Comparative study on covalent and noncovalent endogenous Albumin-Binding \u03b2-Glucuronidase-Activated SN38 prodrugs for antitumor efficacy","volume":"68","author":"Lu","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:53:34Z","timestamp":1779756814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926002750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"alternative-id":["S0168365926002750"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114873","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-glucuronidase-triggered ortho-hydroxyl-mediated cyclization strategy for the efficient delivery of phenolic payloads in antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114873"}}